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OBJECTIVE—The goal of this study was to investigate whether
the effects of common genetic variants associated with fasting
glucose in adults are detectable in healthy children.
RESEARCH DESIGN AND METHODS—Single nucleotide
polymorphisms in MTNR1B (rs10830963), G6PC2 (rs560887),
and GCK (rs4607517) were genotyped in 2,025 healthy European
children aged 9–11 and 14–16 years. Associations with fasting
glucose, insulin, homeostasis model assessment (HOMA)-insulin
resistance (IR) and HOMA-B were investigated along with those
observed for type 2 diabetes variants available in this study
(CDKN2A/B, IGF2BP2, CDKAL1, SLC30A8, HHEX-IDE, and
Chr 11p12).
RESULTS—Strongest associations were observed for G6PC2
and MTNR1B, with mean fasting glucose levels (95% CI) being
0.084 (0.06–0.11) mmol/l, P  7.9  1011 and 0.069 (0.04–0.09)
mmol/l, P  1.9  107 higher per risk allele copy, respectively.
A similar but weaker trend was observed for GCK (0.028 [0.006
to 0.06] mmol/l, P 0.11). All three variants were associated with
lower -cell function (HOMA-B P  9.38  105, 0.004, and 0.04,
respectively). SLC30A8 (rs13266634) was the only type 2 diabe-
tes variant associated with higher fasting glucose (0.033 mmol/l
[0.01–0.06], P  0.01). Calculating a genetic predisposition score
adding the number of risk alleles of G6PC2, MTNR1B, GCK, and
SLC30A8 showed that glucose levels were successively higher in
children carrying a greater number of risk alleles (P  7.1 
1017), with mean levels of 5.34 versus 4.91 mmol/l comparing
children with seven alleles (0.6% of all children) to those with
none (0.5%). No associations were found for fasting insulin or
HOMA-IR with any of the variants.
CONCLUSIONS—The effects of common polymorphisms influ-
encing fasting glucose are apparent in healthy children, whereas
the presence of multiple risk alleles amounts to a difference of
1 SD of fasting glucose. Diabetes 58:2939–2945, 2009
Diabetes is characterized by chronic hyperglyce-mia resulting from a defect in insulin secretionby the pancreatic -cells and/or insulin actionin peripheral tissues. Although the exact mech-
anisms underlying the development of type 2 diabetes
remain unclear, it is known to be triggered by environmen-
tal and lifestyle factors in genetically susceptible individ-
uals (1). Since 2006, an unprecedented number of novel
genetic loci that are reproducibly associated with type 2
diabetes have been identified in genome-wide association
(GWA) studies of adults (1,2). However, the contribution
of known type 2 diabetes genes to differences in fasting
glucose in healthy individuals is only small (3), and in
contrast to the success in the discovery of these genes,
much less is known about common genetic determinants
of fasting glucose.
Common genetic variants in G6PC2 (glucose-6-phospha-
tase catalytic 2) (4), GCK (glucokinase) (5), GCKR (glu-
cokinase regulator) (6), and MTNR1B (melatonin receptor
1B) (7,8,9) have only recently been identified as the first
loci regulating fasting glucose in GWA studies of healthy
diabetes-free adults. G6PC2, GCK, and GCKR all encode
proteins that are key regulators of the provision of fasting
glucose. Rare mutations in GCK play a role for the
development of maturity-onset diabetes of the young
(MODY), a disorder characterized by mild stable fasting
hyperglycemia (10). G6PC2, GCK, and GCKR thus repre-
sent likely candidates for altering an individual’s physio-
logic glucostat set point in the absence of disease. In
contrast, MTNR1B was the only fasting glucose loci shown
to alter the risk of type 2 diabetes in addition to fasting
glucose levels in healthy individuals (7,8,9). The reported
associations are most likely due to increased expression of
MTNR1B in pancreatic -cells and melatonin-mediated
impaired insulin secretion in risk allele carriers (8) and
demonstrate that the identification of fasting glucose
genes through GWA studies of healthy individuals can lead
to the discovery of type 2 diabetes loci and provide
important insight into the pathogenesis of type 2 diabetes.
The majority of diabetes diagnosed before adulthood
has until recently been attributed to type 1 diabetes, and
with the majority of research focusing on adults only,
limited data exist for children and adolescents with type 2
diabetes (11,12,13). Concomitant with the obesity epi-
demic, the prevalence and incidence of type 2 diabetes in
youth have risen worldwide (11,12,14), and it is estimated
that 45% of pediatric patients now diagnosed with diabetes
in the U.S. have type 2 diabetes (12). Exposure to common
genetic polymorphisms recently shown to contribute to
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elevated glucose levels in adulthood starts at conception,
yet it is unknown whether their effects can be detected in
childhood. To understand whether common glucose-
raising alleles exert an influence on glycemic control early
in life and in the relative absence of insulin resistance,
secondary to chronic obesity commonly present in older
individuals (13), we studied associations of G6PC2, GCK,
and MTNR1B as well as levels of fasting glucose, insulin,
homeostasis model assessment (HOMA)-insulin resistance
(HOMA-IR), and HOMA-B in a population-based study of
healthy European children (n  2,025) aged 9–11 and
14–16 years.
RESEARCH DESIGN AND METHODS
We studied children who participated in the European Youth Heart Study
(EYHS), a mixed longitudinal population-based study of which the design and
data collection have been described previously (15,16). DNA of children from
Estonia (city and county of Tartu) and Denmark (city of Odense) was
available for the study. Baseline measurements took place between 1997 and
1999 in Denmark and Estonia, and another survey of children aged 9 years was
conducted in 2003 in Denmark only. Similar protocols for data collection were
used in both countries. The study complied with international guidelines on
biomedical research and ethical procedures of each participating country.
Written informed consent was obtained from the child’s parent or legal
guardian after they were given a full written explanation of the goals of the
study and its possible hazards, discomfort, and inconvenience. In addition,
children had all procedures verbally explained to them, together with any
possible discomfort they might encounter, and were given the option to
withdraw at any time.
At each study location a defined population of children was identified, and
from this population a two-stage cluster sample of boys and girls aged 9–11
and 14–16 years was randomly selected. The primary sampling units were
schools, and secondary units were school registers. Age-groups 9–11 and
14–16 years were chosen to broadly represent children either side of puberty;
in addition, detailed assessment of pubertal stage was performed as outlined
below. In total, 2,194 children agreed to participate, with a similar proportion
participating in each country (76% in Estonia and 75% in Denmark).
Each child had a blood sample taken and underwent a physical examina-
tion including anthropometric and blood pressure measurements using the
same equipment in both countries. Blood samples were collected after an
overnight fast and analyzed by a Clinical Pathology Accreditation (CPA)
accredited laboratory in Bristol and Cambridge, England. Glucose concentra-
tions were measured by standard methods using Olympus AU600 random-
access analysers. Plasma-specific insulin was determined by two-site
immunometric assays with either 125I or alkaline phosphatase labels. Be-
tween-laboratories correlations were 0.94–0.98 for 30 randomly selected
samples analyzed in both Bristol and Cambridge. HOMA was used to estimate
insulin resistance (HOMA-IR  [fasting glucose (mmol/l)  insulin (U/ml)]/
22.5) and -cell function (HOMA-B [insulin (U/ml) 20]/[glucose (mmol/l)
3.5]) (17), both of which have been validated as surrogate markers in healthy
children (18). These indexes based on fasting glucose and insulin concentrations
reflect primarily hepatic insulin sensitivity/resistance (19), and HOMA-IR and
fasting insulin have been suggested to predominantly measure hepatic rather than
peripheral insulin resistance in prepubertal and early pubertal adolescents (20).
Weight was measured in light clothing to the nearest 0.1 kg using a
calibrated beam balance scale. Height was measured without shoes to the
nearest 0.5 cm using a transportable Harpenden stadiometer. Four skin-fold
measurements (triceps, biceps, subscapula, and suprailiac) were taken on the
left side of the body according to the criteria described by Lohman et al. (21).
All measurements were taken twice and in rotation. If the difference between
the two measurements differed by more than 2 mm, a third measurement was
taken and the two closest were averaged. BMI was calculated as weight in
kilograms divided by the square of height in meters. Pubertal status was
assessed by trained personnel according to Tanner’s five-level classification of
biological maturity (22) using breast development in girls and pubic hair in
boys. Children were later classified as being prepubertal (Tanner stage 1) or
at early (Tanner stages 2–3) or later (Tanner stages 4–5) stages of puberty.
Genotyping. Single nucleotide polymorphisms (SNPs) most significantly
associated with fasting glucose in recent GWA studies and located in G6PC2
(rs560887), GCK (rs4607517), and MTNR1B (rs10830963) were the focus of
this report and were genotyped at the Medical Research Centre Epidemiology
Unit Research Laboratory using the TaqMan SNP Genotyping Assays (Applied
Biosystems, Warrington, U.K.). In addition, SNPs that were identified in the
initial round of type 2 diabetes GWA studies and had previously been
successfully genotyped in EYHS were also included to compare effect sizes
between type 2 diabetes and fasting glucose loci in children. These included
SNPs located in or near CDKN2A/B (rs1063192 and rs10811661), IGF2BP2
(rs11705729), CDKAL1 (rs7756992, rs10946403, and rs10946398), SLC30A8
(rs13266634), HHEX-IDE (rs5015480), and chromosomal region 11p12
(rs1828390).
The genotyping assays were undertaken on 10 ng of genomic DNA in a 5 l
384-well TaqMan assay using a PTC-225 Thermal Cycler (MJ Research,
Watertown, MA). The ABI PRISM 7900HT Sequence Detection System (Ap-
plied Biosystems, Warrington, U.K.) was used for end point detection and
allele calling. The call rate was 98.9%, and concordance of 44 duplicate
samples was 100%. All 12 SNPs were in Hardy-Weinberg equilibrium (all P
values  0.07).
Statistical analyses. Statistical analyses were performed using Stata 10.1. A
total of 2,025 of 2,194 individuals had DNA available and had complete
information on anthropometry, glucose, and insulin. Of all 2,025 participants,
results from 21 children were excluded from analyses based on either
nonfasting status (n  17) or due to glucose levels 7 mmol/l (n  4).
Linear regression models, assuming an additive effect, were used to test
associations between each SNP and log-normalized outcomes (for insulin,
HOMA-IR, and HOMA-B), adjusting for age, sex, country, and biochemistry
laboratory. For all associations significant at 0.05 or less, differences by
age-group, country, and sex were investigated.
To investigate the joint contribution of all SNPs associated with fasting
glucose in children, a genetic predisposition score was calculated by adding
the number of risk alleles based on SNPs associated with fasting glucose
(G6PC2, GCK, MTNR1B, and SLC30A8). The score followed and approxi-
mated normal distribution and ranged from 0–7, the maximum observed
number of risk alleles carried by children in the study. Sensitivity analyses
were performed using alternative scores excluding GCK or the type 2 diabetes
gene SLC30A8.
RESULTS
Overall mean  SD fasting glucose was 5.1  0.39 mmol/l
(Table 1). Strongest overall associations were observed
for variants in G6PC2 and MTNR1B (Table 2), two of the
genes recently identified as common genetic determinants
of fasting glucose in healthy adults. Variant rs560887 in
G6PC2 showed the largest effect size, with fasting glucose
being a mean 0.084 mmol/l (95% CI 0.06–0.11; P  7.9 
1011) higher for each copy of the common C-allele
(frequency 0.70 in HapMap CEU). For rs10830963 in
MTNR1B, glucose levels were 0.069 mmol/l (0.04–0.09;
P  1.9  107) higher for each copy of the minor G-allele
(frequency 0.30 in HapMap CEU). A similar but weaker
trend was observed for rs4607517 in GCK (0.028 mmol/l
[0.006 to 0.06; P  0.11]). Each of the three variants was
also associated with significantly lower -cell function
(P  9.38  105, 0.004, and 0.04, respectively).
Of the type 2 diabetes–susceptibility genes that were
investigated, rs13266634 in SLC30A8 was the only variant
significantly associated with fasting glucose, with an effect
size of 0.033 mmol/l (95% CI 0.01–0.06; P  0.01) per copy
of the common C-allele (frequency 0.75 in HapMap CEU);
no significant association was observed with HOMA-B.
The three SNPs in CDKAL1 were associated with HOMA-B
(P  0.03) but not fasting glucose (Table 3). None of the
observed associations were attenuated by adjustment for
measures of adiposity estimated by either BMI or sum of
the skin-fold thicknesses. No significant associations were
present between any of the variants and fasting insulin or
HOMA-IR (see supplemental Tables 1 and 2 in the online
appendix, available at http://diabetes.diabetesjournals.org/
cgi/content/full/db09-0374/DC1).
Using the genetic risk score, we examined the additive
effect of an increasing number of risk alleles of glucose-
associated variants on children’s glucose levels (Fig. 1).
Mean fasting glucose was 0.06 mmol/l (95% CI 0.04–0.07;
Ptrend  7.1  10
17) greater for each additional risk allele
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of G6PC2, GCK, MTNR1B, and SLC30A8. GCK was in-
cluded in this score despite not reaching conventional
levels of statistical significance in this study because
previous evidence demonstrated its association with fast-
ing glucose in healthy children (5). In addition, the fasting
glucose effect sizes of GCK and SLC30A8 were found to be
of similar magnitude. The total difference in fasting glu-
cose between individuals carrying zero (0.5% of all chil-
dren) compared with seven (0.6%) glucose-rising risk
alleles was 0.43 mmol/l.
Alternative scores using risk alleles of G6PC2,
MTNR1B, and GCK or G6PC2, MTNR1B, and SLC30A8
showed a similar trend. Similar results were obtained
when investigating the additive effect of fasting glucose
risk alleles on HOMA-B levels, with children having a
greater number of risk alleles showing successively lower
-cell function (Ptrend  3.0  10
5; supplemental Fig. 2 in
the online appendix).
We observed no difference in associations by age-group,
sex, or country (all interaction P values 0.05), except for
rs10830963 in MTNR1B for which a significantly stronger
effect on fasting glucose was observed in the older age-
group (interaction P value  0.004). Among the 9–11 year
olds, fasting glucose levels were 0.037 mmol/l (95% CI
0.005–0.07) higher for each minor G-allele, whereas this
effect was 0.11 mmol/l (0.07–0.15) for children aged 14–16
years. More detailed investigation showed similar effect
modification of rs10830963 on fasting glucose by pubertal
status based on Tanner stage, with greater effect sizes at
later stages of maturity (interaction P value  0.02),
independent of age, sex, or country. In prepubertal chil-
dren (Tanner stage 1) the per-allele difference in fasting
glucose was 0.046 mmol/l (0.01–0.08) but 0.071 mmol/l
(0.04 to 0.18) at Tanner stages 2–3 and 0.11 mmol/l
(0.07–0.16) at Tanner stages 4–5. Although the effect of
rs10830963 on HOMA-B did not differ significantly by
age-group (P  0.41), its effect was found to be marginally
stronger at later Tanner stages (interaction P value 
0.079), mirroring the interaction observed for fasting
glucose.
DISCUSSION
This is the first study to show that common genetic
variants in G6PC2, MTNR1B, and GCK, all of which are
associated with fasting glucose in diabetes-free adults,
significantly influence levels of fasting glucose and/or
-cell function in healthy children.
Importantly, the joint effects of these common variants
were additive and substantial. Higher levels of glucose
were observed in children carrying more risk alleles, with
a difference of 1 SD of fasting glucose comparing the
small proportion of children in the extreme groups with
the lowest, opposed to the highest, genetic susceptibility.
Effect sizes of MTNR1B and G6PC2 variants in children
of this study were close to those recently reported in
adults, with differences in fasting glucose of 0.08 and 0.06
mmol/l per risk allele, respectively (7,4). Weedon et al. (5)
previously showed that rs1799884 in GCK is associated
with fasting glucose in adults and also children of the Avon
Longitudinal Study of Parents and Children (ALSPAC)
cohort. Compared with this study and a more recent
meta-analysis of adults reporting an effect size of 0.06
mmol/l (7), we observed a somewhat weaker and nonsig-
nificant effect for rs4607517, a SNP in perfect linkage
disequilibrium with rs1799884 in European-descent Hap-
Map participants (r2  1), suggesting that low power is
likely to underlie the lack of statistical significance in our
study.
In the absence of any direct measure of -cell function,
we use HOMA-B. We report significant associations for
MTNR1B, GCK, and G6PC2 with HOMA-B in healthy
children, adding to the evidence from initial GWA studies
(7) and showing for the first time that early effects on
-cell function can be demonstrated for these loci. GCK
and G6PC2 are expressed in the pancreas and code for
TABLE 1
Mean values of selected characteristics of the study population by country, sex, and age-group
Denmark Estonia
Girls Boys Girls Boys
9–11
years
14–16
years
9–11
years
14–16
years
9–11
years
14–16
years
9–11
years
14–16
years
n 409 177 349 158 234 257 230 190
Age (years) 9.6 15.5 9.8 15.5 9.5 15.4 9.6 15.5
Prepubertal children/Tanner 1 (%) 96.7 0.0 100.0 1.9 91.5 0.0 92.6 1.1
Pubertal children/Tanner 2–3 (%) 3.3 6.0 0.0 5.7 8.6 8.6 7.4 23.2
Pubertal children/Tanner 4–5 (%) 0.0 94.0 0.0 92.4 0.0 91.4 0.0 75.8
Fasting glucose (mmol/l) 5.0 5.1 5.1 5.3 4.9 5.0 5.1 5.2
Fasting insulin (pmol/l)* 45.9 73.2 37.9 68.2 36.6 70.7 32.9 57.0
HOMA-IR* 1.7 2.8 1.4 2.6 1.3 2.6 1.2 2.2
HOMA-B* 101.7 144.7 79.2 128.7 90.0 164.0 68.1 109.1
Triglycerides (mmo/l) 0.83 1.04 0.75 0.92 0.77 0.85 0.69 0.67
HDL cholesterol (mmol/l) 1.49 1.40 1.61 1.33 1.44 1.45 1.51 1.32
LDL cholesterol (mmol/l) 2.68 2.45 2.55 2.28 2.71 2.56 2.52 2.29
Systolic blood pressure (mmHg) 101.5 108.8 103.8 118.5 100.0 107.3 101.3 114.2
Diastolic blood pressure (mmHg) 60.8 64.1 61.2 63.7 59.1 64.1 58.7 62.5
Height (cm) 139.5 165.9 139.9 174.8 137.3 164.9 137.6 174.1
Weight (kg) 34.0 57.5 34.3 63.6 31.4 55.4 31.9 61.7
BMI (kg/m2) 17.4 20.9 17.4 20.8 16.6 20.3 16.8 20.3
Sum of skin-fold measurements (cm) 40.1 53.2 33.0 37.0 31.5 44.3 24.8 28.2
*Data are median values.
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proteins that play an important role for the regulation of
glucose levels. MTNR1B is a less obvious candidate, and
expression of MTNR1B in pancreatic -cells and the role
of MTNR1B risk alleles for impaired insulin secretion has
only recently been identified (8).
Importantly, adjustment for BMI or skin-fold thickness
did not alter the observed associations, and our findings
thus demonstrate that the effects of genetic variants
contributing to elevated levels of fasting glucose are
present from an early age and can help to identify children
at different levels of -cell function, independent of their
level of adiposity. We provide epidemiological evidence
for common genetic variants contributing to variation in
the human homeostatic set point for blood glucose levels
from an early age, which may or may not translate into
clinically significant differences and longer term complica-
tions related to chronic hyperglycemia.
In contrast, SLC30A8 was the only type 2 diabetes locus
investigated that was found to be associated with varia-
tions in fasting glucose in children, with an effect that did
not follow a clear linear trend/additive model and did not
influence levels of HOMA-B. SLC30A8 encodes a zinc
transporter involved in insulin secretion by the -cell (2)
and has previously been shown to be associated with
fasting glucose levels in healthy adults (3) but not chil-
dren. Studies of adults have likewise shown an effect of
SLC30A8 (3,23) and also HHEX (23,24) and CDKAL1 (24)
on -cell function assessed by HOMA-B (3) as well as oral
glucose tolerance test or hyperinsulinemic-euglycemic
clamp (23,24) measures. In children, CDKAL1 was the
only locus significantly associated with HOMA-B, and
future studies including a larger number of children may
be able to detect significant effects for loci of smaller effect
sizes.
We did not observe any associations with fasting insulin
or HOMA-IR, consistent with previous studies in adults
that showed little or no association between glucose or
type 2 diabetes–susceptibility genes with insulin levels or
insulin resistance (3,7,23,24), pointing toward -cell func-
tion rather than insulin action underlying the higher glu-
cose levels and risk of type 2 diabetes caused by variants
identified in recent GWA studies (8,25). It is important to
consider the clinical and public health implications of such
interindividual differences in fasting glucose among nor-
moglycemic individuals. Elevated adult glucose concentra-
tion per se is a strong predictor of future type 2 diabetes
(26), and Morrison et al. (27) have shown that the presence
of impaired fasting glucose in girls of Caucasian and
African descent aged 9–10 years is associated with an
increased risk of type 2 diabetes 1 decade later. Higher
levels of fasting glucose have been linked to an increased
risk of coronary heart disease in healthy individuals and
those with type 2 diabetes (28,29), but the strength of this
association in the nondiabetic glucose range is a matter of
debate (30). Whether early differences in fasting glucose
levels due to genetic susceptibility translate into an in-
creased risk of type 2 diabetes and related metabolic and
cardiovascular disorders and whether or how these are
modified by environmental risk factors remain to be
investigated.
Children included in this study were randomly selected
by age to broadly represent groups before and after
entering puberty. Although we found no evidence for
differences in the observed associations by age, sex, or
country, one exception is noteworthy. The MTNR1B vari-
ant, recently associated with fasting glucose in adults (7)
and located in a gene coding for one of the two known
human melatonin receptors (31), displayed a significantly
stronger effect on fasting glucose—and to a somewhat
lesser degree on HOMA-B—in older or pubertal children
compared with younger or prepubertal children. The
MTNR1B gene is expressed in -cells in both human and
rodent islets, and the translated receptor is thought to
mediate the inhibitory effect of melatonin on insulin
secretion (8,32). During puberty, children go through a
transient state of relative insulin resistance (12,14,33).
Although our cross-sectional epidemiological findings do
not allow strong causal or temporal inference, they may
point toward the effect of MTNR1B on -cell function
being more pronounced in the context of insulin resis-
tance and increased secretory demand. The recent obser-
vation that the increased expression of MTNR1B in
G-allele carriers of rs10830963 was greater in older indi-
viduals than those 45 years of age (8) lends some
support to this hypothesis.
We conclude that effects of genetic variants contributing
to differences in fasting glucose and -cell function are
apparent at early ages. Although the strength of each
5.70
5.50
5.30
5.10
4.90
4.70
4.50
0 1 2 3 4 5 6 7
Fa
sti
ng
 P
la
sm
a 
G
lu
co
se
 (m
m
ol
/L
)
10 28664 335588518 1282
Number of risk alleles 
Number of individuals in each category
Percentage of individuals in each category (%) 0.5 15.13.4 17.731.027.3 0.64.3
FIG. 1. Mean (95% CI) fasting plasma glucose level (mmol/l) by number of glucose risk alleles (MTNR1B, G6PC2, SLC30A8, and GCK).
C. KELLINY AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 58, DECEMBER 2009 2943
individual association appears to be of limited clinical
significance, joint additive effects are substantial, amount-
ing to a difference in 1 SD in fasting glucose in healthy
children. Ongoing efforts in the identification of novel
fasting glucose genes will help develop more comprehen-
sive genetic risk scores that can identify a larger propor-
tion of children with elevated fasting glucose levels and
decreased -cell function and provide useful tools for
future studies of the longer-term consequences of chronic
elevations in fasting glucose, as well as opportunities for
targeted prevention of diabetes.
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